{"title":"葛兰素史克将其非核心OTC品牌的最后一部分出售给Aspen Pharmacare","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i4.1731","DOIUrl":null,"url":null,"abstract":"GlaxoSmithKline has agreed to sell a portfolio of international OTC brands, excluding the troubled anti-obesity drug alli® (orlistat, 60 mg), to South Africa’s Aspen Pharmacare for £164 M (US$263 M). The divested brands generated sales of approximately £60 M (US$94 M) in 2011. The acquisition will drive growth for Aspen in Latin America and Southeast Asia.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"36 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"GSK Divests its Final Tranche of Non-Core OTC Brands to Aspen Pharmacare\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i4.1731\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"GlaxoSmithKline has agreed to sell a portfolio of international OTC brands, excluding the troubled anti-obesity drug alli® (orlistat, 60 mg), to South Africa’s Aspen Pharmacare for £164 M (US$263 M). The divested brands generated sales of approximately £60 M (US$94 M) in 2011. The acquisition will drive growth for Aspen in Latin America and Southeast Asia.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"36 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i4.1731\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i4.1731","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
GSK Divests its Final Tranche of Non-Core OTC Brands to Aspen Pharmacare
GlaxoSmithKline has agreed to sell a portfolio of international OTC brands, excluding the troubled anti-obesity drug alli® (orlistat, 60 mg), to South Africa’s Aspen Pharmacare for £164 M (US$263 M). The divested brands generated sales of approximately £60 M (US$94 M) in 2011. The acquisition will drive growth for Aspen in Latin America and Southeast Asia.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
